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Abstract 
Background: Neo-angiogenesis is an essential process in physiological and pathological conditions. 
However, it is a complex process.  Several studies demonstrated that intra-tumoural microvessel number is a 
significant predictor of metastasis and clinical outcome in many tumours, including oral malignancies. The 
immuno-surveillance cells, mast cells and eosinophils are implicated in the biological behaviour of tumours.  
Nevertheless, their function in tissues is uncertain. Mast cells are involved in homeostatic regulation of blood 
vessels as well as host defence.  In some malignancies, high mast cell density has been found to correlate 
with favourable prognosis. However, others reported unfavourable associations. Tumour associated tissue 
eosinophilia is a well-known phenomena. It has been associated with good and poor prognosis. However, the 
role of eosinophils in tumours remains controversial.  Therefore, this study was designed to investigate the 
prognostic value of microvessel, mast cell and eosinophil densities in the context of clinico-pathological 
parameters and survival in squamous cell carcinoma of the tongue. Materials and Methods: Anti-CD105 and 
anti-tryptase monoclonal antibodies were utilized to highlight and count microvessels and mast cells 
respectively in 81 cases of tongue squamous cell carcinoma. Eosinophils were demonstrated using carbol 
chromotrope histochemical stain. The densities were counted per mm2 and correlated with patients’ outcome 
and other clinico-pathological parameters using non-parametric tests and student’s t-test.  Clinically, the cases 
were divided into 4 main groups depending on survival time, lymph-node or distant metastasis. Results: The 
5 year survival was significantly lower in patients with a low mast cell density than those with a high density 
(p=0.006, Kruskal-Wallis test). The survival group-A demonstrated significantly higher mast cell and 
microvessel numbers than group-D (p=0.007, student’s t-test) respectively.  Patients with well- differentiated 
squamous cell carcinoma had significantly higher numbers of mast cells when compared to patients with 
poorly differentiated squamous cell carcinoma (p<0.05, student’s t-test). The lymph node involvement 
correlation between the survival group-A and survival group-D was also significant (p=0.001, Mann-Whitney U 
test).  Conclusion: Data from this study indicates that accumulating mast cells in tumours play a part in 
inhibiting tumour progression and is potentially angiogenic in tumours. 
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Introduction 
Neo-angiogenesis is an essential step for many 
physiological processes, such as growth, wound 
healing, organ regeneration and reproductive 
functions. Abnormal blood vessel growth occurs in 
several pathological conditions, including tumour 
growth and metastasis [1]. Angiogenesis is 
however a complex multistep process, and one 
that is not fully understood. A cascade of events 
involving endothelial migration and proliferation, 
microvessel differentiation and anastomosis, and 
extracellular remodelling has been suggested 
[2,3]. One of the main differences between normal 
and pathological angiogenesis is that in the latter, 
the vessels are highly disorganised and their walls 
have many openings, leading to ‘leaky vessels’ [4]. 
Tumour-associated angiogenesis is important in 
maintaining tumour growth and facilitates its 
metastatic spread through connections with the 
existing vasculature [5,6]. Several studies 
demonstrated that intra-tumoural 
neovascularisation is a significant predictor of 
metastasis and clinical outcome in oral 
malignancies [7-9]. The association between 
microvessel density (MVD), clinicopathological 
parameters and prognosis in oral squamous cell 
carcinoma (SCC) has been investigated.  Data 
shows significant correlation between MVD, 
tumour behaviour and survival [10-13]. 
Immuno-surveillance cells, namely mast cells 
(MCs) and eosinophils (Eos) have been implicated 
in the biological behaviour of tumours. Although 
MC function in tissues is still largely unknown, 
their activation occurs through both immune and 
non-immune mechanisms. They are involved in 
homeostatic regulation of nerves and blood 
vessels as well as host defence.  MC mediators 
are known to affect endothelial cells by inducing 
vasodilatation and recruitment of inflammatory 
cells. It has been postulated that MCs play a role 
in promoting angiogenesis in some malignant 
tumours and their association with various 
tumours has been described [14-17]. 
In some malignancies, high mast cell density 
(MCD) has been found to correlate with favourable 
prognosis. However, others reported unfavourable 
associations [18-20]. Eosinophils are rare 
granulocytes that are normally associated with 
allergic diseases or responses to various parasitic 
infections. Tumour associated tissue eosinophilia 
(TATE) has been observed for many decades in 
tumours involving larynx, oesophagus, pharynx, 
skin, breast, cervix, lung and gastrointestinal 
system [21-29]. Nevertheless, the genuine role of 
Eos in tumour stroma remained a controversial 
Page 30   
Original Article   
www.ljm.org.ly
 
 
 
  Libyan J Med, AOP: 070110
 
topic. Both, favourable and unfavourable 
prognoses have been reported in TATE [30-35]. 
It was not until the early 1980’s, when a study of 
TATE in head and neck cancer gained attention. In 
the majority of the reports, TATE was associated 
with favourable outcomes [36,37].  Nevertheless, 
unfavourable association has also been reported 
[38]. 
TATE may represent a local inflammatory 
reaction leading to tumour cell damage [39], but 
products of tumour necrosis may itself induce 
tissue eosinophilia [40].  Abundant Eo infiltration 
has been noticed near hemosiderin deposits in 
solid tumours. This raised the assumption that 
accumulation of Eo could be due to presence of 
intracellular erythrocytic pathogens [41]. 
Furthermore, attachment of activated eosinophil to 
tumour cells and loss of its proteins, in addition to 
detection of IL-5 suggested that Eos might play a 
role in the host defence mechanism [42]. 
Currently, the exact functional relevance of MC 
and Eo association with various tumours remains 
indefinite. The correlation of MVD, MCD and 
eosinophil density (ED) with prognosis in tongue 
carcinoma is also uncertain. Therefore, this study 
was designed to investigate the prognostic value 
of these cells and MVD in the context of clinico-
pathological parameters and survival in SCC of the 
tongue. 
 
Material and Methods 
Patient selection: 
Eighty one patients, treated and followed at 
Leeds Dental Institute between 1994 and 1998 
who were diagnosed as having SCC of the tongue 
and who had enough follow-up information, were 
enrolled in the study. None of the patients had 
received chemotherapy or radiotherapy before 
surgery.  Informed consent for research and 
approval by local research ethics committees was 
obtained (04/Q1107/27).  Tissue sections were 
reviewed and representative paraffin embedded 
tissue blocks selected. 
 
Immunohistochemical staining procedure: 
The standard streptavidin-peroxidase 
conjugated method was used throughout the 
research. For microvessel staining, 4µm sections 
from each tumour block were dewaxed. 
Endogenous peroxidase was blocked using 2% 
hydrogen peroxide in methanol for 20 min. Each 
step of incubation was followed by a thorough 
washing of the sections with tris buffered solution 
(TBS).  Sections were primarily incubated with 
casein 1/10 v/v for 5 min to suppress non-specific 
binding of subsequent reagents. After incubation 
with primary antibody against CD105 (Endoglin) 
receptor (clone SNGH, NeoMarkers, Fremont, CA 
USA), mouse monoclonal; 1/40 v/v dilution for 
overnight incubation, the sections were then 
treated with secondary biotinylated antibodies for 
30 min followed by streptavidin for 30 min. Finally, 
all slides were treated with 3, 3` Diaminebenzidine 
(DAB, Sigma D-5637) and counterstained with 
Mayer’s haematoxylin. 
For MCs demonstration, serial sections from the 
same blocks used to evaluate MVD were cut and 
stained for mast cell tryptase. After dewaxing the 
sections, antigen retrieval using proteolytic 
enzyme (0.1% chymotrypsin) for 15 min in an 
incubator at 37Cº was performed.  Sections were 
given a thorough wash with TBS then incubated 
with 1/10 v/v casein for 10 min, followed by 
monoclonal anti-mast cell tryptase antibody 
(B25487, Calbiochem), 1/250 dilution for 60 min. 
The rest of the procedure was continued as 
described previously. 
Eos was demonstrated using carbol chromotrpe 
(CC) stain; well known in demonstrating 
eosinophils [43]. After dewaxing and washing in 
running tap water, the sections were stained with 
Harris' haematoxylin solution to stain nuclei for 5 
min. 
The sections were then washed in water, 
differentiated in 1% acid alcohol, blued in Scott's 
tap water substitute and washed in tap water.  The 
sections were then stained with carbol 
chromotrope solution for 30 min followed by a 
water wash for two min.  The sections were then 
dehydrated cleared and mounted in DPX. 
For evaluation of the inter/intra-examiner 
consistency, 22 sections were selected randomly 
from the sample and the re-counting procedure for 
the three variables was performed by the same 
examiner. 
Another colleague, who was not involved in the 
research but familiar with the procedure, was 
asked to carry out the same re-counting 
procedure. 
 
Estimation of MVD, MCD and ED: 
The MVD was assessed in tumour and peri-
tumoural areas following similar principles 
described by Weidner et al [44]. Sections were 
scanned at x100 magnification and areas of high 
vascular density identified (hot spots).  Individual 
vessels were then counted in at least three fields 
with the aid of a grid in 0.23 mm--------2 using a 
x25 objective.  Any discrete, brown stained 
endothelial cells were considered as a countable 
microvessel, although some of the vessel lumens 
were unclear. The highest figure in the counted 
hot spot fields was considered as the MVD for a 
given case.  By using the same counting method 
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as for MVD evaluation, MCs were counted in hot 
spots, in an area of 0.09 mm2 using a x40 
objective. The highest obtained value was 
considered as the MCD for a given case. 
ED counts were determined using the same 
method used for counting MCs and the highest 
eosinophil count achieved was recorded as the 
ED. 
 Survival classification: 
Clinically, the cases were divided into 4 main 
survival groups; A, B, C and D depending on 
survival time, lymph-node or distant metastasis 
(Table 1). Only one case fell under survival group 
C and on statistical advice, it was moved into 
group D, thereforemaking the survival groups to go 
down to 3. The MVD, MCD and ED counts were 
each divided into two groups depending on the 
median values, high= ≥ 29, low= < 29 for MVD; 
high= ≥ 17, Low= < 17 for MCD and high= ≥ 48, 
low= <48 for ED. 
 
Table 1: Classification and description of the survival 
groups 
Group Description 
A  60 m+ with no recurrence or metastasis 
30-59 m with recurrence or metastasis 
B  60 m+ with recurrence or metastasis 
C  30-59 m with recurrence or metastasis 
D  <30 m regardless of recurrence or 
metastasis 
m= months 
 
Statistical analysis: 
For statistical analysis, Scientific Package for 
Social Sciences for Windows (version 14.0) 
(SPSS, Inc, Chicago, IL) was used to analyse 
variables and produce graphical representation. 
The 5 year survival rate was correlated with the 
high and low MVD, MCD and ED groups using 
Cox’s Regression analysis. The nonparametric 
Kruskal-Wallis test was used to test possible 
significance.  Assessment of the MVD, MCD and 
ED in relation to the survival groups was also 
performed by the non-parametric Kruskal-Wallis 
test and student’s t-test. The histological grades 
were correlated with MVD, MCD and ED using the 
Mann-Whitney U test. 
 
Results 
The MCs that were distant from the tumour 
edges appeared large and darkly stained, while 
the intra-tumoural MCs were smaller in size, lightly 
stained and showed signs of degranulation (Fig. 
1). CC stain demonstrated eosinophils quite nicely 
(Fig. 2).  
 
  
 
Figure 1: Anti-MC tryptase immunohistochemical 
staining demonstrating intact MCs distant from tumours 
(A, arrow) and degranulating intra-tumoural MCs (B, 
arrow) (original magnification x400 approx). 
 
Sixty five percent (n=53) of the cases were 
males and 35 % (n=28) were females. The mean 
age was 54.9 yr and 65.6 yr for males and 
females respectively.  Only one male case was of 
unknown age.  84% (n=68) of the cases were well-
differentiated, 11.1% (n=9) were moderately 
differentiated and 4.9% (n=4) were poorly-
differentiated SCC. 
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Figure 2: Carbol chromotrope stain demonstrating 
eosinophils in the control section (central eosinophilic 
granuloma). (Mag. x400 approx). 
 
Node metastasis was present in 21.0% (n=17) of 
the cases and recurrence was present in 13.6% 
(n=11). The survival rate was calculated from the 
date of surgery to the date of death or date of the 
information obtained if patients were still alive.  In 
cases where cause of death was unknown, 
patients dying within 2 years from the day of 
surgery were considered ‘dead of the disease’. 
Survival time was obtained for all cases except 
one case. The minimum survival time was 1 
month, maximum was 115 months and the mean 
overall survival was 52.36 months (±37.4 SD). The 
mean survival, age, and the histopathological 
parameters of each survival group are given in 
tables 2&3. The median score values for ED, 
MCD, MVD and survival in months are shown in 
table 4. 
 
Table 2; Number of cases, overall survival mean and 
standard deviation, mean age and standard deviation in 
each survival group. 
Group  N  OS(mean± SD)  Age (mean±SD) 
A 36  79.4±21.1  58.9±12.4 
B 13  78.3±9.9  60.9±8.4 
C 1  48  49 
D 30  8.8±6.9  66.6±17.5 
N= Number of cases, OS = Overall survival in months 
 
The score for MVD ranged from 0 to 66 with a 
mean of 27.9 ± 15.7, MCs ranged from 3 to 58, 
with a mean of 20.69 ± 11.3 and 0 to 303 with a 
mean of 59.4± 55.8 for ED.  The inter and intra-
examiner consistency counts revealed insignificant 
differences. 
 
 
Table 3: Number(n) of SCC cases with grade, 
proportion of MVD, proportion of MCD, proportion of ED 
and the number of positive node cases in each survival 
group. 
Differentiation 
(n)  Gro
up 
WD MD  PD 
MVD  MC
D  ED 
N
M 
A  33 2 1  24.3±12.
3 
32.1±
15.1 
60.6±5
0.5  0 
B  10 3 0  20.8±6.7  27.3±
16.6 
57.9±5
5.8  8 
C  1 0  0  -  -  - 0 
D  24 4 3  16.6±10.
4 
22.9±
15.2 
58.6±6
3.6  9 
WD= Well differentiated, MD= moderately 
differentiated, PD= MD= poorly differentiated, NM= 
node metastasis. Note;One case is of unknown survival. 
 
Table 4: The median values for ED,MCD,MVD and 
survival in moths according to tumor differentiation, 
lymph node metastasis and tumor size. 
  ED MCD MVD  Survival
WD SCC  48 17  29  60 
MD SCC  68 19  24  40 
PD SCC  39 15  35  8 
LN +ve  48 17  28  60 
LN -ve  48 18  30  16 
T1  41 16  28  60 
T2  56 22  33  60 
T3  54 19  36  60 
T4  38 16  13  6 
ED=Eosinophil density, MCD= mast cell density, 
MVD= microvascular density, WD= Well differentiated, 
MD= moderately differentiated, PD= MD= poorly 
differentiated, LN =lymph node, T1-T4= tumor size. 
. 
Survival at 5 years was 68% in patients with 
high MCD count compared to 38% in those 
patients with a low count. The MVD groups and 
the overall 5 year survival correlation was 
insignificant. However, the correlation was 
significant when only survival group A and D were 
tested (p = 0.02, Mann Whitney U test).   
Furthermore, the survival group-A cases showed a 
higher number of blood vessels than group-D 
cases (p<0.05, student’s t-test) (Table 2). 
The 5 year survival was significantly shorter for 
patients with a low MCD than those with a high 
MCD count (Fig. 3, Kruskal-Wallis test, p=0.006). 
The survival group-A had significantly higher mast 
cell numbers than group-D (p=0.007, student’s t-
test) but not with survival group-B. The well- 
differentiated SCC cases had a significantlyhigher 
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number of MCs than the poorly differentiated SCC 
cases (p<0.05, student’s t-test).  
 
 
 
Figure 3: Cox regression survival curve evaluating the 
high MCD (≥17) and low MCD (<17) groups in relation to 
overall 5 year survival (P = 0.006, Kruskal-Wallis test). 
 
The high and low ED groups did not show any 
difference in 5 year survival.   There were no 
differences in ED among the survival groups. The 
number of microvessels difference in the two ED 
groups was insignificant. Also, no correlation was 
found between ED and SCC differentiation. The 
spearman’s correlation test revealed no linear 
association between the MCD and ED. The MVD 
and MCD showed no correlation with ED. 
There were no differences in the percentages of 
MVD, MCD or ED in the positive and negative 
lymph node cases. When overall 5 year survival 
was correlated with nodes, negative node cases 
survived better than those cases with positive 
nodes, though the correlation was insignificant 
(Mann-Whitney U test, p=0.091). Nevertheless, 
there was a significant correlation between node 
and the survival group-A and survival group-D 
(Mann-Whitney U test, p=0.001). 
 
Discussion 
Neoangiogenesis is a complex process; 
multifactorialy regulated and thought to be 
fundamental in tumour development and 
progression.   Although several studies have 
suggested that angiogenesis might be an 
independent prognostic factor, others have failed 
to show any correlation between tumour 
vascularisation and survival [7,9,13,45-47]. Use of 
different antibodies to define endothelium, different 
methodology in assessment of MVD and inter-
observer variation could contribute to these 
discordant results. Various endothelial markers 
including CD34, CD31, vascular endothelial 
growth factor (VEGF) and von Willebrand factor 
have been used for evaluation of neoangiogenesis 
in tumours. It is well known that these markers are 
not specific for neo-angiogenic vessels and can 
express on the pre-existing host vessels. 
Recently, use of anti-CD105 antibody has been 
widely accepted due to its relative specificity in 
identifying microvessels in various tumours [48-
49]. The counting method is critical in determining 
the number of vessels, MCs or Eos. Hot spots are 
invariably located in the stroma around tumour 
edges, therefore rendering random counting of 
fields meaningless. However, values obtained 
from averaging multiple hot spot fields would 
make little or insignificant difference from the 
highest hot spot count. 
Furthermore, in certain tumours, the number of 
vessels or MCs is probably related to stromal 
volume, thus tumours with more stroma might 
exhibit more vessels and cells. These variations in 
the amount of stroma and tumour cells in various 
counting fields might influence the traditional 
counting procedure. Pazouki et al [50] counted the 
highest number of microvessels (MVD) per 
surface area of oral tumours and compared that 
with the conventional stereological method of 
measuring microvascular volume. The volume but 
not the MVD method showed significant and linear 
increase in vascularity with increasing severity of 
the disease.   In a previous study, the density 
counting method for TATE was thought to be more 
appropriate than the classical counting method 
[51]. In fact, the suggested cut off value (50/mm2) 
that demarcates the low and high ED cases was 
very close to the median value (48/mm2) that was 
used in this study to delineate the low and high ED 
cases. 
Tumour expansion is a progressive process and 
therefore continuously stimulates new vessel 
formation.  Several studies of oral SCCs, including 
tongue, demonstrated a significant increase in 
vascularity during the tumour progress [52-55]. 
Moreover, the endoglin expression in oral SCC 
was significantly higher in comparison to the 
normal healthy mucosa and sequentially related to 
the tumour grades [50]. 
In this series of tongue SCC, there was no 
association between MVD and the overall 5 year 
survival or survival groups. In addition, the non-
parametric tests failed to detect any correlation 
between MVD and tumour differentiation or nodal 
metastasis. These results are in agreement with 
Amar et al [46], who failed to demonstrate any 
association between MVD and patient prognosis 
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or histological features in SCC of the tongue. A 
study of 33 cases of oral SCC revealed higher 
MVD with increasing tumour and node stages but 
not with survival [7]. 
In the current study, the high and low MVD 
groups showed no differences in survival. 
Interestingly, survival group-A showed higher 
numbers of microvessels and MCs in comparison 
to survival group-D. This pattern of vascularity 
between the two groups is probably related to the 
MCs and not to the tumour progression. However, 
this remains speculative. It has been postulated 
that growth of solid tumours is dependent upon 
adequate blood supply through stroma. Although 
the precise mechanism by which MCs are 
implicated in angiogenesis is not fully understood, 
several angiogenic factors, such as histamine, 
proteases (tryptase and chymase), cytokines 
(tumour necrosis factor-α, interleukin-8), VEGF 
and fibroblast growth factor (FGF-2) that are 
released by the accumulating MCs in and around 
tumours have been suggested [56-57]. In animal 
studies, tumours of mast cell deficient mice 
revealed lower angiogenesis than normal mice 
[15]. A significant correlation between MCs and 
microvascular counts was shown in oral mucosa 
and our results are in line with those of the 
previous oral SCC studies [58-59]. Furthermore, 
there had been linear increase of MCs from 
normal mucosa to the development of squamous 
carcinoma that suggested they may upregulate 
angiogenesis, possibly through their tryptase 
content [58].Oral tissues are highly vascular. Most 
studies that investigated MVD in the head and 
neck looked at samples from different locations, 
whilst in this study, the samples were exclusively 
from the tongue.  Possibly, tumours of the tongue 
are not as reliant on neovascularisation. 
Our results showed that the high mast cells 
group had longer survival (68%) than the low mast 
group (38%). Also, the mean MCD and MVD in 
survival group-A were significantly higher than 
those of survival group-D. On the other hand, the 
mean MCD difference between survival groups A 
and B were insignificant. The latter group 
comprised cases with recurrences or nodal 
metastasis but with survival time extending up to 
60 months. This demonstrates that the MCD is a 
factor independent of metastasis or recurrence. 
Nevertheless, no correlation was found with other 
histopathological parameters. 
Accumulation and degranulation of MCs around 
tumour areas has been observed in previous 
reports and in this study (Fig. 1). However, the 
functional significance of this phenomenon is 
contentious. MCs are conventionally divided into 
either tryptase positive or tryptase and chymase 
positive subtypes, and may undergo phenotypic 
changes.  Significant increases of MC containing 
tryptase and chymase subpopulations were found 
at the tumour invasion areas, where its role is 
thought to degrade extracellular matrix. The 
tryptase containing MCs were found at the 
intratumoural stroma and play a role in 
angiogenesis [59]. The predominant MC type in 
tissues may be determined by environmental 
needs. 
However, the coexistence of tryptase-
expressing MCs and chymase and tryptase-
expressing MCs in physiological conditions 
reflects a natural balance that contributes to tissue 
homeostasis [60].   
Many reports believe that MCs play roles in 
angiogenesis and progression of tumours 
including oesophagus [15], pulmonary 
adenocarcinoma [16], colorectal carcinoma [17], 
and lip cancer [61]. On the contrary, high mast cell 
associated tumours revealed significantly different 
outcomes in ovarian cancer [14], colorectal cancer 
[62], breast cancer [63], and prostatic 
adenocarcinoma [64]. 
Based on the clinical observation, data from Tan 
et al [62] suggest that MCs have a cytotoxic effect 
on cancer cells; there was a direct correlation 
between the number of MCs and clinical outcome, 
which are in line with our findings. 
The current view is that MCs are versatile in 
function and capable of regulating inflammation, 
host defence, and innate immunity by elaboration 
of several chemokines and cytokines. MC 
accumulation in tumours is probably part of a 
response to tumour derived chemoattractant [65]. 
In vitro generated MCs express natural cytotoxicity 
against tumour cells [66].  They are also cytotoxic 
for mammalian tumours when supplemented with 
iodide and H2O2. The latter is released from the 
tissue phagocytes and initiates MC degranulation 
and liberation of the cytotoxic endogenous 
peroxidase from its granules [67]. 
The anti-tumour activity by mast cells has also 
been attributed to MCs production of tumour 
necrosis factor (TNF-α), which is directly cytotoxic 
to certain tumour cells [68]. Cultured human MCs 
were found to induce apoptosis in Jurkat T-
leukemia cells suggesting a possible role in 
immune surveillance against tumour cells that may 
extend beyond TNF-α sensitive tumour [69]. 
Significant increases in peri-tumoural MCs of lip 
carcinoma showed histochemical changes and 
signs of degranulation [70]. These features 
suggest that mast cells contribute to the host-
defence reaction of the tumour. 
Recently, strong evidence that MCs can 
suppress the growth of tumour cells through an 
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indirect mechanism involving heparin and 
fibroblasts adjacent to tumour cells has been 
demonstrated [71]. 
In addition, several studies showed an anti-
tumour effect of low molecular weight heparin in 
animal models of malignancy, and the 
improvement of cancer outcome in humans [72-
73]. 
These data demonstrates the diversity of MC 
biological functions. Thus, MC could be 
detrimental to tumour via its components; the 
tryptase, chondroitin sulphate and cell mediators 
(e.g. IL-1, IL-4, IL6, TNF-α).   Also, MC 
components, such as histamine, heparin and other 
growth factors may promote tumour progress and 
metastasis [74]. 
This study failed to find any association between 
the ED and survival, angiogenesis or the other 
histopathological parameters.   In literature, poor 
and good prognosis has been associated with 
TATE.   Many factors could contribute in the 
conflicting reports. Counting methodology, number 
of cases included in the study, biopsy or surgical 
samples, tumour differentiation and site are 
examples of the contributing factors. In the current 
study, and just for our interest, the cases were re-
counted using the classical method that was 
described by Lowe & Fletcher [26], and the cases 
were classified into low, moderate and high TATE.  
However, neither clinical nor histopathological 
association was detected. 
Tumour-derived eosinophil chemotactic factors 
and anti-tumour activity of eosinophils have long 
been described in the literature [75-77]. However, 
the available data are insufficient. TATE could 
represent a response to local inflammatory 
reaction. In vivo studies revealed that MC 
chymase is a potent stimulus for inflammatory cells 
recruitment following mast cell activation [78]. 
In conclusion, from our studies and literature 
review, there is mounting evidence that 
accumulating MCs in tumours play a part in 
inhibiting tumour progression, probably via 
cytotoxic components and mediators. Also, MCs 
are potentially angiogenic in tumours.   On the 
other hand, Eos did not show any correlation with 
the patients’ outcomes and their presence is 
probably due to potent chemotactic factors 
released by mast cells. 
To the best of our knowledge, this is the first 
report on the significance of MCs in tongue 
carcinoma and strongly emphasizes the need for 
further studies to clarify more of these fascinating 
biological effects. 
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